drugset
drugset / Trial / NCT06683053

Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

NCT06683053 ↗

Phase 3 Active not recruiting 90 enrolled Conrado Roberto Hoffmann Filho
RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims to evaluate whether the use of a 25 mg dose of empagliflozin compared to the 10 mg dose used would bring additional benefits in the improvement outcomes of the Kansas City Cardiomyopathy Questionnaire (KCCQ SST), in the 6-minute walk test (6MWT) without causing significant side effects.

Timeline

Start
2023-03-17
Primary completion
2024-04-29
Completion
2025-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg —
Subject Empagliflozin Small molecule 25 mg —

Indications

congestive heart failure